Action required: Please refresh your browser
We have recently implemented some changes that require a hard refresh of your browser: Please hold down the CTRL-key and press the F5 key.
After a successful hard refresh, this message should not appear anymore.
More details about this topic are available here »
Sensorium Therapeutics Expands Board Leadership with Addition of Simba Gill, Ph.D., as Independent Director | ||
By: PR Newswire Association LLC. - 30 Jan 2024 | Back to overview list |
|
Gill brings decades of leadership experience building biotech companies, transformative platforms and developing products The company announces first Development Candidate Nomination, SENS-01, developed as a rapid-acting, well-tolerated therapeutic for anxiety, with immediate plans to start IND enabling studies and enter the clinic by 2025 BOSTON, Jan. 30, 2024 /PRNewswire/ -- Sensorium Therapeutics (Sensorium), a biotechnology company leveraging machine learning, medicinal chemistry and neuroscience to develop nature-inspired neuroactive medicines for neuropsychiatric and neurological diseases, today announced it appointed Simba Gill, Ph.D., as an independent director to its Board. "Simba's strategic leadership insights will be critical as we advance our lead program, SENS-01, toward the clinic and progress our pipeline to address areas of unmet need across the CNS space," said Alexandra Glucksmann, Ph.D., CEO of Sensorium. "Patients are in need of treatments that are more effective and with fewer side effects. I am confident Simba's experience in company building and optimizing patient impact will strengthen our efforts." "Sensorium's team uniquely integrates multiple disciplines to create a platform that opens up the possibility of transforming the treatment of neuropsychiatric and neurological diseases," said Dr. Gill. "I greatly look forward to supporting Sensorium as the company advances its platform and potential products into clinical development and beyond." The company also announces Development Candidate Nomination of SENS-01, is a rapid-acting and well-tolerated new chemical entity which is being developed for patients with anxiety, with a novel mechanism of action from standard of care. Sensorium initiated IND-enabling studies in 2024 and plans to progress to the clinic in 2025. About Sensorium Therapeutics View original content to download multimedia:https://www.prnewswire.com/news-releases/sensorium-therapeutics-expands-board-leadership-with-addition-of-simba-gill-phd-as-independent-director-302047508.html SOURCE Sensorium Therapeutics |
||
|
||
Copyright 2024 PR Newswire Association LLC. | Back to overview list |